PMID- 27932758
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20181202
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 41
IP  - 11
DP  - 2016 Nov 28
TI  - [Expressions of HER2 and Topo IIalpha in breast cancer and 
its clinical 
      significance].
PG  - 1143-1147
AB  - To detect the expressions of human epidermal growth factor receptor 2 (HER2) and 
      Topo IIalpha in breast cancer, and to analyze the clinical significance of 
      neoadjuvant chemotherapy for the anthracycline-based drugs.
 Methods: The HER2 
      and Topo IIalpha gene and protein expressions in cancer tissues from 189 patients 
      with breast cancer were detected by fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC). And the objective response rate (ORR) and 
      pathological complete rate (pCR) were analyzed.
 Results: The HER2 protein 
      expression in 46 patients (24.3%) and Topo IIalpha protein expression in 55 patients 
      (29.1%) was 3+ by IHC or they were 49 (25.9%) and 94 (49.0%) by FISH, 
      respectively. The ORR and pCR in HER2 negative or positive patients were 47.4% 
      and 20.3% or 32.7% and 16.3%, respectively, with significant differences (All 
      P<0.05). The ORR and pCR in Topo IIalpha positive or negative patients were 69.1% and 
      36.0% or 28.4% and 2.2%, respectively, with significant differences (All 
      P<0.05).
 Conclusion: FISH and IHC were consistent in the determination of HER2 
      expression whereas they were inconsistent in the determination of Topo IIalpha 
      expression. The amplification of Topo IIalpha can effectively improve the effect of 
      the adjuvant treatment effect of the anthracyclines.
FAU - Shuai, Ping
AU  - Shuai P
AD  - Department of Pathology, Gannan Medical College, Ganzhou Jiangxi 341000, China 
      shuaiping11w@sina.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - Anthracyclines/*pharmacology/therapeutic use
MH  - Antibiotics, Antineoplastic
MH  - Breast Neoplasms/*chemistry/*genetics/*therapy
MH  - DNA Topoisomerases, Type II/*physiology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Neoadjuvant Therapy
MH  - Receptor, ErbB-2/*physiology
MH  - Treatment Outcome
EDAT- 2016/12/10 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/12/10 06:00
PHST- 2016/12/10 06:00 [entrez]
PHST- 2016/12/10 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.11817/j.issn.1672-7347.2016.11.005 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Nov 28;41(11):1143-1147. doi: 
      10.11817/j.issn.1672-7347.2016.11.005.